This paper is only available as a PDF. To read, Please Download here.
Abstract
Antiandrogen therapy for androgen-induced baldness is in its infancy. In men, because
of side effects, topical antiandrogens appear to hold the most promise. Assessing
changes in scalp hair growth may be difficult, however, and hirsutism provides a useful
model for testing the efficacy of topical antiandrogens. Systemic administration of
5a-reductase inhibitors may also eventually prove to be helpful in the treatment of
male-pattern baldness, but side effects and long-term risks are unknown. In women,
systemic antiandrogens appear to be a reasonable option for therapy and produce a
good subjective response. Further research is needed, however, ta document the long-term
risks and efficacy of systemic antiandrogen therapy in women.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinics in DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Male hormone stimulation is prerequisite and an incitant in common baldness.Am J Anat. 1942; 71: 451-480
- Hair follicles and associated glands as androgen targets.Clin Endocrinol Metab. 1986; 15: 319-339
- Testosterone metabolism in the skin.Arch dermatol. 1975; 111: 1496-1502
- Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia.Br J dermatol. 1983; 109: 249-252
- The metabolism of testosterone by human male scalp skin.J Endocrinol. 1973; 57: 111-121
- Regulation of human hair growth by steroid hormones: I. Testosterone metabolism in isolated hairs.J Clin Endocrinol Metab. 1974; 38: 811-819
- Androgen resistance syndromes.Am J Physiol. 1982; 243: E81-E87
- Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency—a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity.J Steroid Biochem. 1979; 11: 637-645
- Steroid 5-alpha reductase deficiency.Pediatr Adolesc Endocrinol. 1981; 8: 156-170
- Adrenal androgenic female-pattern alopecia: sex hormones and the balding woman.Cleve Clin Q. 1983; 50: 111-122
- Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.Br J dermatol. 1977; 97: 247-254
- Low sex-hormone binding globulin levels in young women with diffuse hair loss.Br J dermatol. 1982; 106: 331-336
- The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors.J Clin Endocrinol Metab. 1984; 59: 51-55
- Ann Intern Med. 1976; 85 (moderator): 630-636
- Treatment of idiopathic hirsutism with spironolactone.Dermatologica. 1982; 165: 194-196
- Aspects of endocrinological treatment of hair diseases.in: Orfanos CE Montagna W Stuttgen G International Congress on Hair Research 1st, Hamburg, Germany 1979 Springer-Verlag, Berlin1981: 312-317
- Medical treatment of male pattern alopecia (androgenic alopecia).Head Neck Surg. 1985; 7: 336-339
- Treatment of hirsutism with 5 alpha-reductase inhibitors.Clin Endocrinol Metab. 1986; 15: 391-405
- The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.Endocrinology. 1983; 113: 569-573
- Inhibition of 5 alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid.J Biol Chem. 1981; 256: 7998-8005
- The effects of N, N-diethyl-4-methyl-3-oxo-4-Aza-5α-androstane-17β-carboxamide, a 5 alpha-reductase inhibitor and antiandrogen, on the development of baldness in the stumptail macaque.J Clin Endocrinol Metab. 1987; 65: 188-193
- The stumptailed macaque as a model for androgenetic alopecia: effects of topical minoxidil analyzed by use of the folliculogram.Clin dermatol. 1988; 6: 177
- Hirsutism.Ann Intern Med. 1987; 106: 95-107
- Treatment of hirsute women with cimetidine.N Engl J Med. 1980; 303: 1042
- Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.Br J Obstet Gynaecol. 1985; 92: 983-985
- Treatment of hirsutism with spironolactone.JAMA. 1982; 247
- Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.Fertil Steril. 1981; 36: 468-471
- The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.Fertil Steril. 1985; 43: 200-205
- Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.J Endocrinol Invest. 1983; 6: 23-27
- Therapeutic effects of spironolactone in polycystic ovary syndrome.Obstet Gynecol. 1983; 61: 429-432
- Spironolactone in combination drug therapy for unresponsive hirsutism.Fertil Steril. 1985; 43: 878-882
- A novel use of spironolactone: treatment of hirsutism.J Clin Endocrinol Metab. 1980; 51: 429-432
- Treatment of moderate idiopathic hirsutism with a cream containing canrenone (an antiandrogen).Dermatologica. 1982; 165: 636-639
- Diffuse hair loss in women.Cutis. 1978; 22: 190-195
- Oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia.BrJ dermatol. 1985; 112: 124-125
- Oral anti-androgen treatment of common baldness in women.Br J dermatol. 1982; 107 (Suppl.): 20
Article info
Identification
Copyright
© 1988 Published by Elsevier Inc.
